Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-P01 in advanced malignant solid tumors
NCT03662815Phase 1Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Feb 2018
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-P01 in advanced malignant solid tumor, sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Objective Response Rate at 2 years and Number of participants experiencing clinical and laboratory adverse events at 1 year. Status: unknown.
02
Drugs
iNeo-Vac-P01
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT03662815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662815.